ASCO 2024 - Matteo Levisetti
ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy. But there are still many cancers where this class of drugs doesn’t work.
In this post-ASCO interview with CUE Biopharma chief medical officer Matteo Levisetti, Levisetti tells pharmaphorum editor-in-chief Jonah Comstock about how his company’s tumour-specific T-cell engagers could create new opportunities for cancer immunotherapies to succeed.
During the interview, Levisetti describes CUE’s ASCO data in head and neck cancer – early data that showed an impressive 20-month-plus median survival. He also discusses what makes the company’s pipeline stand out and how it could shake up cancer immunotherapy.
Levisetti also gets into CUE’s future plans and talks about the insights he took away from the conference in Chicago two months ago, including thoughts about the ongoing challenges in cancer vaccines and how they might be overcome.
Check out the video below for an interesting and expansive look at advances in immunotherapy.
